CAUTION CONCERNING FORWARD-LOOKING STATEMENTS Certain statements made today constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "expects," "intends," "projects," "plans," "believes," "estimates," "targets," "anticipates," and other similar words or expressions, or the negative thereof, generally can be used to help identify these forward-looking statements. Examples of forward-looking statements include st ...

JIM FITTERLING, CHAIR AND CEO September 11, 2025 Macroeconomic Backdrop Consistent with 2Q Earnings Strong Moderate/Mixed Weak Changes vs. Prior Update Dow 3Q Updates DOW PRESENTS AT MORGAN STANLEY LAGUNA CONFERENCE 1. Average 2022 – 2024 % of Total Dow Revenue excluding Corporate and Hydrocarbons & Energy 2. Current consensus expectations for 3Q25 EBITDA of $770MM as of September 9, 2025 2 Market Vertical (% of Revenue1 ) NAA LAA EMEAI China Rest of World Packaging ~30% Infrastructure ~40% Consumer ~20% Mo ...

Forward-Looking Statements Jim Taiclet, Chairman, President and CEO Evan Scott, Chief Financial Officer Thursday, September 11, 2025 8:30 a.m. – 9:05 a.m. PT Lockheed Martin Corporation Morgan Stanley 13th Annual Laguna Conference This presentation contains statements that, to the extent they are not recitations of historical fact, constitute forward-looking statements within the meaning of the federal securities laws, and are based on Lockheed Martin's current expectations and assumptions. The words "belie ...

Morgan Stanley's 13th Annual Laguna Conference Joe Hinrichs President & Chief Executive Officer 9.11.2025 Forward Looking Disclosure This information and other statements by the company may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to, among other items: projections and estimates of earnings, revenues, margins, volumes, rates, cost-savings, expenses, taxes, liquidity, capital expenditures, dividends, share repurchases or other financia ...

Financial Performance & Growth - Freshworks' ARR exceeded $840 million[24], with a 2-year CAGR of 20%[24] - The company achieved 18% YoY revenue growth and a 27% adjusted FCF margin in Q2 2025[24] - Freshworks is on track for $1.3 billion+ ARR by 2028[34] - The company projects revenue between $822.9 million and $828.9 million for 2025, representing 14%-15% YoY growth[232] - Non-GAAP income from operations is projected between $153 million and $157 million for 2025[232] Customer Base & AI - Freshworks has 74,000+ paying customers across 120+ countries[21] - Mid-market and Enterprise customers account for >60% of total ARR[24] - Freddy AI is now a >$20 million ARR business[24, 96] Employee Experience (EX) - EX remains a durable 20%+ growth engine[34] - EX customers with >$100K ARR increased by 32% YoY[58] - Databricks achieved 23% ticket deflection via self-service using Freshworks[61]

Financial Performance - Zenvia's net revenues increased from BRL 231 million in Q2 2024 to BRL 286 million in Q2 2025[4] - Non-GAAP adjusted gross profit increased from BRL 100.2 million in Q2 2024 to BRL 101 million in Q2 2025[11] - EBITDA decreased from BRL 34 million in Q2 2024 to BRL 11 million in Q2 2025[6] - General & Administrative (G&A) expenses decreased by 25% from H1 2024 to H1 2025, from BRL 64.6 million to BRL 48.2 million[14] Segment Performance - Zenvia Customer Cloud (SaaS) revenues increased 23% year-over-year[7] - CPaaS revenue mix increased, impacting gross profit[7] - SaaS revenue mix increased from 66% to 72%, while CPaaS decreased from 34% to 28%[8] - Non-GAAP adjusted gross margin for SaaS increased slightly from 54.5% to 55.4%[11] - Non-GAAP adjusted gross margin for CPaaS decreased from 43.3% to 24.1%[11] Strategic Initiatives - The company is on track to deliver expected savings of BRL 30-35 million from workforce reduction[13] - Zenvia Customer Cloud is on track for 25-30% growth in FY 2025[7]

Financial Performance - Kroger's identical sales without fuel increased by 34% in Q2 2025[5] - E-commerce sales grew by 16% compared to last year[5,6] - GAAP operating profit was $863 million[5] - Adjusted FIFO operating profit reached $1091 million[5] - GAAP EPS was $091[5] - Adjusted EPS grew by 12%[5] Guidance - The company updated its FY25 identical sales without fuel guidance to 27%-34%[10] - Operating profit guidance is $48 billion - $49 billion[10] - EPS guidance is $470 - $480[10] - Free cash flow guidance remains at $28 billion - $30 billion[10]

Company Overview - Culp, Inc is a major North American marketer of mattress and upholstery fabrics with global manufacturing in the US, China, Haiti, and Vietnam[6] - Culp's fiscal year 2025 revenue was $213.2 million[7] - The bedding segment accounts for 53% of Culp's fiscal 2025 revenue, while the upholstery segment accounts for 47%[8] Market Position and Strategy - Culp holds a 20-25% market share in the $500-600 million domestic mattress fabric and cover market[10] - Culp holds an 8-10% market share in the $1.5-$2.5 billion domestic upholstery fabric market[13] - Restructuring actions completed in fiscal year 2025 are projected to yield $10 to $11 million in annualized cost savings and efficiency gains[21] - Additional integration actions in fiscal year 2026 are expected to generate ~$6 million in total annualized additional benefits[32] - Pricing initiatives in fiscal year 26 are expected to generate ~$2.5 million annualized margin improvement in bedding segment[32] Liquidity and Financial Health - As of August 3, 2025, Culp's total liquidity was $28.7 million, including cash and availability from credit lines[15] - Estimated proceeds from a Canadian real estate sale will add $3 million to liquidity, bringing the total to $31.7 million[15] - Culp has U S Federal NOL carryforwards totaling ~$88.1 million as of April 27, 2025[16] Market Outlook - The mattress industry may be nearing the end of a period of low demand[35] - UBS forecasts 4% growth in mattress industry sales in 2026 and 8% growth in 2027[40]

Financial Performance and Growth - Royalty Pharma is on track to deliver $4.7 billion+ in top-line revenue in 2030, representing a 10%+ CAGR from 2020 to 2030[10, 353] - The company has delivered consistent mid-teens ROIC (Return on Invested Capital)[11, 354] - Royalty Pharma's 2030 top- and bottom-line outlook is >10% above analyst consensus[11, 354] - The company's goal is at least mid-teens TSR (Total Shareholder Return) over the next 5 years[11, 354] - Portfolio Receipts are expected to reach approximately $3.1 billion in 2025, based on guidance provided on August 6, 2025, plus expected contribution from the Imdelltra royalty acquisition announced on August 25, 2025[21] Market Dynamics and Strategy - The average annual royalty market size was $6 billion from 2020-2024, representing ~130% growth from the prior 5-year period[10, 353] - Royalty Pharma has a market share of ~50% from 2020 to present, which is ~4-fold higher than the next largest competitor, with >70% share of transactions ≥$500 million[120, 191] - Repeat partners have driven ~30% of announced transaction value since 2020[120, 191] - 87% of biopharma executives would consider royalties as part of their capital raising plans over the next 3 years[110] - Since 2012, Royalty Pharma has deployed approximately $27 billion of capital, with 65% allocated to approved products and 35% to development-stage therapies[46, 49]

MZE782 Phase 1 Trial Results - MZE782 demonstrated an excellent safety profile with no serious adverse events observed[18] - MZE782 exhibited linear pharmacokinetics (PK) across single doses ranging from 30 mg to 960 mg, with a half-life of approximately 11 hours[18, 32] - The trial showed up to a 42-fold increase in urinary phenylalanine (Phe) excretion and a 68-fold increase in urinary glutamine (Gln) excretion at Day 7[18] - MZE782 induced a dose-dependent initial estimated glomerular filtration rate (eGFR) dip, similar to SGLT2 inhibitors[18] Planned Phase 2 Trials in 2026 - The company plans to initiate Phase 2 trials for both Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) in 2026[18] - The PKU Phase 2 trial aims to demonstrate proof-of-concept (PoC) with plasma Phe reduction as the endpoint[56] - The CKD Phase 2 trial will focus on demonstrating PoC with proteinuria reduction as the primary endpoint[56] MZE782 Therapeutic Potential - MZE782 aims to deliver potential best-in-class plasma phenylalanine (Phe) reduction with a good safety profile for PKU patients[17] - MZE782 could be a new mechanism of action (MoA) to address CKD patients with inadequate response to current therapies, including SGLT2 inhibitors[56] Company Financial Position - The company has a strong cash position with an expected runway into 2028[12]